S. 5059: A bill to amend the Public Health Service Act to streamline the review of biosimilar biological products.

S. 5059 is a federal bill in the 119th Congress. Currently, federal health regulators must follow a multi-step review process that includes specific consultation or notification steps before approving generic versions of complex biological medicines, known as biosimilars. This bill removes one of those… See its sponsors, how members voted, and a plain-English breakdown on PolityLens.